Search

The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.

… Monday, December 28, 2020 Summary Researchers at Memorial Sloan Kettering have learned how chromosomal instability allows cancer cells to avoid immune defenses and metastasize (spread). The discovery opens up potential new avenues for treatment. Cancer cells are known for spreading genetic chaos. As

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.

… Friday, August 5, 2022 On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low  breast cancer  that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial

Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.

… Tuesday, November 14, 2017 Summary Edi Brogi, a breast pathologist, explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease. A breast cancer diagnosis often starts when a change is found

Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.

… Wednesday, October 25, 2017 Summary Emily Herzlin, who teaches meditation through MSK’s Integrative Medicine Service , offers insight into how it can help people with cancer, survivors, and caregivers. Can the simple acts of being still, noticing your thoughts, and focusing on your breath really be transformative

Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.

… Tuesday, May 20, 2025 Comedy vs Cancer, the official comedy benefit show for blood cancer research at Memorial Sloan Kettering Cancer Center (MSK), returned to Jazz at Lincoln Center’s Frederick P. Rose Hall. The sold-out, one-night-only event raised over $2.3   million to support lifesaving blood cancer

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.

… Friday, August 12, 2022 On August 11, 2022, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab deruxtecan (also known as T-DXd or Enhertu®) for the treatment of advanced non-small cell lung cancer (NSCLC) driven by mutant HER2. Trastuzumab deruxtecan was previously approved for

Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.

… Wednesday, March 6, 2019 VIDEO | 03:47 Expanding Organ Preservation Surgery in Esophageal Cancer Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients. Video Details

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

… Wednesday, April 20, 2016 Summary Genomic sequencing of tumors is allowing cancer researchers to tailor treatments to patients in a way that was previously not possible, allowing a more targeted, personalized approach to cancer care. Increasingly, the focus of research is on finding the right combination

Get to know Marissa Gredler, a postdoctoral fellow in the Sloan Kettering Institute.

… Friday, March 27, 2020 Summary As part of Women’s History Month, we are profiling some of MSK’s star female graduate students and postdoctoral fellows training to be leaders in their fields. Marissa Gredler is a postdoctoral fellow in the Zallen lab  in the Sloan Kettering Institute. When and how did

An MSK study found a rise in lumpectomies and a decline in mastectomies — reversing a trend that experts say was leading to the overtreatment of breast cancer.

… Wednesday, July 13, 2022 When Kate Delp was diagnosed with stage 2 breast cancer , she faced a decision: Should she have a lumpectomy or a mastectomy ? “From what I’d heard about mastectomy, I knew that it was a very invasive surgery and difficult to go through,” says Kate, who lives in New Jersey and